11-10 :: October 2011

nanotimes

Companies Facts

pher Anzalone, President and CEO of Arrowhead. “The combination of these assets and Arrowhead’s existing RNAi technologies results in what we believe to be the broadest RNAi therapeutics company in the world, with unparalleled delivery solutions and licenses granting broad freedom to operate within the three primary siRNA formats.”

Furthermore, Arrowhead Research has appointed Bruce Given, M.D. to the position of Chief Opera- ting Officer of the Company effective October 26, 2011.

On September 30, 2011, the Company closed a private placement of approximately 14.5 million shares of common stock priced at market for $0.38 per share. Gross proceeds were approximately $5.5 million and will be used to fund current operations.

“We are making good progress in advancing our clinical and preclinical nanomedicine technology platforms and this capital raise helps us to continue our momentum,” said Christopher Anzalone, Chief Executive Officer of Arrowhead. “We are proud to bring in such high quality new investors in an at mar- ket transaction, particularly in light of current market conditions.”

http://www.arrowheadresearch.com S

ingapore Nanostart (OTCQX: NASRY) investment BioMers has successfully concluded a round of

financing for around SGD6 million (approx. EUR3.5 million). Its new investors include a further venture capital fund and several private investors. Nanostart

is investing pro rata in this financing round and thereby keeping Nanostart Singapore Early Stage Venture Fund’s share in BioMers largely constant at about 24%.

“Investors had a very keen interest in acquiring a sta- ke in BioMers, which confirms the enormous potenti- al the company has for decisively shaping the market for esthetic dental correction.” Andreas Kröll, Mana- ging Director of Nanostart Asia, commented: “Inve- stors had a very keen interest in acquiring a stake in BioMers, which confirms the enormous potential the company has for decisively shaping the market for esthetic dental correction.”

The new funding is intended for the further expan- sion of BioMers. This includes building a new pro- duction facility in Singapore, expanding the sales and marketing team and sales and marketing support activities focusing on Singapore, the US and selected countries in Europe.

http://www.biomersbraces.com B

ruker Corporation (NASDAQ: BRKR) reported financial results for the third quarter ended

September 30, 2011. In the third quarter of 2011, revenue was $418.4 million, an increase of 35% compared to $310.2 million in the third quarter of 2010. Excluding the effects of acquisitions and foreign currency translation, third quarter 2011 re- venue increased organically by 11% year-over-year. GAAP net income for the third quarter of 2011 was $19.8 million, or $0.12 per diluted share, compared to $27.4 million, or $0.17 per diluted share, in the third quarter of 2010. Adjusted net income for the

13